Nabla bio signs second takeda collaboration to advance ai-driven design of protein therapeutics

Cambridge, mass.--(business wire)--nabla bio, a biotechnology company pioneering de novo therapeutics design with generative ai, today announced a new, multi-year research collaboration with takeda. under the terms of the agreement, nabla bio will receive double-digit millions in upfront and research cost payments and is eligible to receive success-based payments that may exceed $1 billion in total. this second collaboration will deploy nabla bio's proprietary biomolecular design platform, join.
TAK Ratings Summary
TAK Quant Ranking